Streetbeat News

AMLX

Amylyx Pharmaceuticals, Inc.

Industry

Biotechnology

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Open

4.26

Mkt cap

288M

Volume

129K

High

4.30

P/E Ratio

-1.10

52-wk high

19.95

Low

4.16

Div yield

N/A

52-wk low

1.57

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Amylyx Pharmaceuticals, Inc. (AMLX) on behalf of investors who purchased securities before November 11, 2022. Investors are encouraged to participate in the investigation.

Portfolio Pulse from

December 18, 2024 | 3:15 pm

Portfolio Pulse from

December 15, 2024 | 3:15 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Amylyx Pharmaceuticals, Inc. (AMLX) stockholders. Investors who purchased AMLX securities before November 11, 2022, are encouraged to participate in the investigation.

Portfolio Pulse from

December 11, 2024 | 7:15 pm

Amylyx Pharmaceuticals, Inc. (AMLX) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included executives and analysts from major financial institutions.

Portfolio Pulse from

November 09, 2024 | 3:15 pm

HC Wainwright & Co. has reiterated its Buy rating for Amylyx Pharma, maintaining a price target of $8.